Medicines & Healthcare products Regulatory Agency

MHRA

Public Assessment Report

National Procedure

Oxybutynin hydrochloride 2.5 mg tablets

oxybutynin hydrochloride

PL 42807/0001

Maxwellia Ltd

LAY SUMMARY

Oxybutynin hydrochloride 2.5 mg tablets
oxybutynin hydrochloride

This is a summary of the Public Assessment Report (PAR) for Oxybutynin hydrochloride 2.5 mg tablets. It explains how this product was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use this product.

This product will be referred to as Oxybutynin Tablets in this lay summary for ease of reading.

For practical information about using Oxybutynin Tablets, patients should read the Patient Information Leaflet (PIL) or contact their doctor or pharmacist.

What are Oxybutynin Tablets and what are they used for?
This product is the same as Oxybutynin Hydrochloride 2.5 mg Tablets (PL 19611/0026) which is already authorised.

The Company responsible for Oxybutynin Hydrochloride 2.5 mg Tablets (PL 19611/0026) has agreed that its scientific data can be used as the basis for the grant of an identical licence for Oxybutynin Tablets.

Oxybutynin Tablets are used to treat the following conditions:
Adults:

- Loss of control in passing water (urinary incontinence), urgency and frequency in patients unable to control their bladder
- Neurogenic bladder disorders (lack of bladder control caused by problems with the nervous system or spinal cord)

Children 5 years or older :

- Loss of control in passing urine (urinary incontinence).
- Increased need or urgency to pass urine
- Night time bedwetting, when other treatments have not worked

How does Oxybutynin Tablets work?
The active substance in Oxybutynin Tablets is oxybutynin hydrochloride. This is one of a group of medicines called anticholinergics or antispasmodics. It increases the volume of the bladder by relaxing the muscle of the bladder wall and helps to control the release of urine.

How is Oxybutynin Tablets used?
The pharmaceutical form of this medicine is a tablet, and the route of administration is by mouth (oral).

The tablets should be swallowed with plenty of water or other fluid, with or without food.

Adults: The recommended dose is 2.5 to 5 mg swallowed two or three times a day. Occasionally, 5 mg four times a day is required.

Elderly (over 80 years): The recommended dose is 2.5 to 5 mg swallowed two or three times a day; however, as the drug can remain in the body for longer in elderly patients, 2.5 to 5 mg twice a day is usually sufficient.

Use in Children
Children over 5 years: The recommended dose is 2.5 to 5 mg swallowed twice a day. Your doctor might decide to increase the dose to three times a day if needed.

Nocturnal enuresis (nighttime bedwetting): The usual dose is 5 mg swallowed two or three times a day. The last dose should be given just before bedtime.

Children under 5 years: Not recommended.

Sometimes the doctor may reduce the dose, especially when their patient has been taking Oxybutynin Tablets for some time.

For further information on how Oxybutynin Tablets is used, refer to the PIL and Summary of Product Characteristics (SmPC) available on the Medicines and Healthcare products Regulatory Agency (MHRA) website.

This medicine can only be obtained with a prescription.

The patient should always take the medicine exactly as their doctor/pharmacist has told them. The patient should check with their doctor or pharmacist if they are not sure.

What benefits of Oxybutynin Tablets have been shown in studies?
Oxybutynin Tablets is considered identical to the previously authorised product with the same benefits and risks. |No new studies have been provided for Oxybutynin Tablets, however, reference is made to the studies for Oxybutynin Hydrochloride 2.5 mg Tablets (PL 19611/0026).

What are the possible side effects of Oxybutynin Tablets?
For the full list of all side effects reported with this medicine, see Section 4 of the PIL or the SmPC available on the MHRA website.

If a patient gets any side effects, they should talk to their doctor, pharmacist or nurse. This includes any possible side effects not listed in the product information or the PIL that comes with the medicine. Patients can also report suspected side effects themselves, or a report can be made on their behalf by someone else who cares for them, directly via the Yellow Card scheme at https://yellowcard.mhra.gov.ukor search for ‘MHRA Yellow Card’ online. By reporting side effects, patients can help provide more information on the safety of this medicine.

Oxybutynin Tablets is considered to be identical to the previously authorised product with the same benefits and risks.

Why was Oxybutynin Tablets approved?
The MHRA decided that the benefits of Oxybutynin Tablets are greater than the risks and recommended that this medicine is approved for use.

What measures are being taken to ensure the safe and effective use of Oxybutynin Tablets?

As for all newly-authorised medicines, a Risk Management Plan (RMP) has been developed for Oxybutynin Tablets The RMP details the important risks of Oxybutynin Tablets, how these risks can be minimised, any uncertainties about Oxybutynin Tablets (missing information), and how more information will be obtained about the important risks and uncertainties.

The following safety concerns have been recognised for Oxybutynin Tablets:

Summary of safety concerns*	
Important identified risks	1. Hypersensitivity to oxybutynin or any of the excipients 2. Precipitation of urinary retention in patients with bladder outflow obstruction 3. Risk of constipation and use in patient with gastro-intestinal obstructive disorders, intestinal atony, paralytic ileus and toxic megacolon 4. Use in patients with severe ulcerative colitis 5. Use in patients with myasthenia gravis 6. Narrow-angle glaucoma 7. Anticholinergic CNS (central nervous system) effects (e.g. hallucinations, agitation, confusion, somnolence) 8. Dependence especially in patients with a history of drug or substance abuse
Important potential risks	9. Use in patients with autonomic neuropathy 10. Use in patients with hepatic or renal impairment 11. Aggravation of tachycardia with unmasking of hyperthyroidism, congestive heart failure, cardiac arrhythmia, coronary heart disease and hypertension 12. Cognitive disorders and cognitive impairment, particularly in the elderly 13. Risk of dental caries, parodontosis or oral candidiasis due to reduction in salivary secretions 14. Exacerbation of oesophagitis in patients with hiatus hernia/gastro-oesophageal reflux and with concomitant use of bisphosphonates 15. Heat stroke due to decreased sweating in high environmental temperatures 16. Increased blood levels of oxybutynin on concomitant use with CYP3A4 inhibitors 17. Reduced efficacy of prokinetic therapies and cholinesterase inhibitors on concomitant use 18. Drowsiness enhanced by alcohol 19. Potentiation of anticholinergic effects if used with other anticholinergic agents 20. Use during lactation
Missing information	21. Use in pregnancy 22. Use in children less than 5 years of age

* Safety concerns have been identified based on the proposed SPC (and current SPC for the reference product)

The information included in the SmPC and the PIL is compiled based on the available quality, non-clinical and clinical data, and includes appropriate precautions to be followed by healthcare professionals and patients. Side effects of Oxybutynin Tablets are continuously monitored and reviewed including all reports of suspected side-effects from patients, their carers, and healthcare professionals.

An RMP and a summary of the pharmacovigilance system have been provided with this application and are satisfactory.

Other information about Oxybutynin Tablets

A marketing authorisation was granted in the United Kingdom on 1 November 2017.

The marketing authorisation application for Oxybutynin Tablets (PL 42807/0001) was originally submitted with a re-classification application to change the legal status from a prescription-only medicine (POM) to a pharmacy medicine (P). If approved, this would mean that Oxybutynin Tablets could be obtained from a pharmacy, by or under the supervision of a pharmacist and a prescription would no longer be required. This aspect of the application was withdrawn by the applicant on 26 May 2017.

On 24 November 2017, a new reclassification application was received for Oxybutynin hydrochloride 2.5 mg tablets (PL 42807/0001) to re-propose a reclassification of legal status from POM to P. However, following a consideration by the Commission on Human Medicines and the evaluation of responses to a public consultation, this application was refused on 10th May 2023. Oxybutynin hydrochloride 2.5 mg tablets is currently a prescription-only medicine (POM). The outcome of the consultation is available here [note link will be inserted once available / pre-publishing of PAR]

The full PAR for Oxybutynin Tablets follows this summary.
This summary was last updated in April 2024.

TABLE OF CONTENTS

I. INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the Medicines and Healthcare products Regulatory Agency (MHRA) considered that the application for Oxybutynin hydrochloride 2.5 mg tablets (PL 42807/0001) could be approved.

The product is approved for the following indications:
Adults:

- Urinary incontinence, frequency and urgency in patients with an unstable bladder (urge syndrome).

- Neurogenic bladder disorders causing detrusor hyperreflexia in conditions such as multiple sclerosis and spina bifida.

Children over 5 years of age:

- Urinary incontinence, urgency and frequency in unstable bladder conditions due to idiopathic overactive bladder or neurogenic bladder disorders (detrusor overactivity)
- Nocturnal enuresis associated with detrusor overactivity, in conjunction with non-drug therapy, when other treatment has failed.

Mechanism of action

Oxybutynin hydrochloride has direct antispasmodic action on the smooth muscle of the bladder detrusor as well as anticholinergic action in blocking the muscarinic effects of acetylcholine on smooth muscle.

These properties cause relaxation of the detrusor muscle of the bladder and in patients with an unstable bladder, oxybutynin hydrochloride increases bladder capacity and reduces the incidence of spontaneous contraction of the detrusor muscle.

This is a national abridged application approved under Regulation 56 of The Human Medicines Regulation 2012, as amended (previously Article 10c of Directive 2001/83/EC, as amended) as an informed consent application. The application cross-refers to the reference product Oxybutynin Hydrochloride 2.5 mg Tablets (PL 19611/0026).

No new non-clinical or clinical data have been supplied and none are required for this informed consent application.

Suitable justification has been provided for non-submission of an Environmental Risk Assessment (ERA). As the application is for an identical version of an already authorised product, no increase in environmental exposure is anticipated and no ERA is required.

The MHRA has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for this product at all sites responsible for the manufacture, assembly and batch release of this product.

A Risk Management Plan (RMP) and a summary of the pharmacovigilance system have been provided with this application and are satisfactory.

A national marketing authorisation was granted in the United Kingdom on 1 November 2017

II. EXPERT REPORT

The applicant cross-refers to the data for Oxybutynin hydrochloride 2.5 mg tablets (Niche Generics Ltd), to which this application is claimed to be identical. This is acceptable.

III. ASSESSOR'S COMMENTS ON THE PRODUCT INFORMATION SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)

The SmPC is in line with that/those for Oxybutynin hydrochloride 2.5 mg tablets .

PATIENT INFORMATION LEAFLET

The patient information leaflet text is in line with that for Oxybutynin hydrochloride 2.5 mg tablets.

LABEL

Label text has been provided.

IV. QUALITY ASPECTS

IV.1 Drug Substance

Drug substance specification

The source and proposed specification of the active substance is in line with the details registered for the cross-reference product.

IV.2. Drug Product

Name

The product has been named in line with current requirements.

Strength, pharmaceutical form, route of administration, container and pack sizes

Oxybutynin hydrochloride 2.5 mg tablets are available in Aluminium / PVC/PVdC strips in boxes of 20, 28, 30, 56, 60, 84 and 120. Not all pack sizes may be marketed

The appearance of the product is identical to that of the cross-reference product.

The proposed shelf life of the product is 3 years with the recommended storage condition 'Store below 25ºC in a dry place'.

The proposed packaging, shelf life and storage conditions are consistent with the details registered for the reference product.

Legal status

Prescription only medicine (POM).

Manufacturers

The proposed manufacturing sites are consistent with the details registered for the cross-reference product and evidence of Good Manufacturing Practice (GMP) compliance has been provided.

Qualitative and quantitative compositions

The composition of the proposed product is consistent with the details registered for the cross-reference product.

Manufacturing process & control of critical steps
The proposed manufacturing processes and process controls are consistent with the details registered for the reference product and the maximum batch size is stated.

Finished product release/shelf life specifications
The finished product specifications at release and shelf-life are in line with the details registered for the cross-reference product.

TSE Compliance
With the exception of lactose, no excipients of animal or human origin are used in the final products.

The supplier of lactose monohydrate has confirmed that it is sourced from healthy animals under the same conditions as milk for human consumption.

The magnesium stearate is confirmed to be of vegetable origin.

This product does not contain or consist of genetically modified organisms (GMO).

V. NON-CLINICAL ASPECTS

As this application is submitted under Regulation 56 of The Human Medicines Regulation 2012, as amended, no new non-clinical data have been supplied and none are required.

VI. CLINICAL ASPECTS

As this application is submitted under Regulation 56 of The Human Medicines Regulation 2012, as amended, no new clinical data have been supplied and none are required.

VII. RISK MANAGEMENT PLAN (RMP)

The applicant has submitted an RMP, in accordance with the requirements of Regulation 182 of The Human Medicines Regulation 2012, as amended. The applicant proposes only routine pharmacovigilance and routine risk minimisation measures for all safety concerns. This is acceptable.

VIII. USER CONSULTATION

A text version of the Patient Information Leaflet (PIL) has been provided with the application, in accordance with legal requirements a mock-up will be provided prior to marketing the product.

IX. OVERALL CONCLUSION, BENEFIT/RISK AND RECOMMENDATION

The quality of the product is acceptable, and no new non-clinical or clinical safety concerns have been identified. The applicant's product is identical to the cross-reference product. The benefit/risk balance is, therefore, considered to be the same as for the cross-reference product and positive.

The Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and labelling are satisfactory, in line with current guidelines and consistent with the cross-reference product.

In accordance with legal requirements, the current approved UK versions of the SmPCs and PILs for these products are available on the MHRA website.

Representative copies of the labels at the time of licensing are provided below.

PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING

CARTON

1. NAME OF THE MEDICINAL PRODUCT

Oxybutynin hydrochloride 2.5mg Tablets

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains:
Active ingredient: 2.5 mg Oxybutynin Hydrochloride

3. LIST OF EXCIPIENTS

Also contains: Lactose, microcrystalline cellulose and E132

4. PHARMACEUTICAL FORM AND CONTENTS

56 Tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Tablets for oral use, to be taken as directed by the doctor.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children

7. OTHER SPECIAL WARNING(S), IF NECESSARY

N/A

8. EXPIRY DATE

EXP: mm/yyyy

9. SPECIAL STORAGE CONDITIONS

Store below 25°C in a dry place

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

N/A

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Licence Holder: Maxwellia Ltd, Alderley Park, Alderley Edge, England, SK10 4TG

12. MARKETING AUTHORISATION NUMBER(S)

PL 42807/0001

13. BATCH NUMBER

Batch: XXXX

14. GENERAL CLASSIFICATION FOR SUPPLY

POM

15. INSTRUCTIONS ON USE

For further information, please read the enclosed leaflet.

16. INFORMATION IN BRAILLE

Braille Text In Line with Directive 2001/83/EC (amended by Directive 2004/27/EC) Human use, Point 42, article 56a :

Oxybutynin hydrochloride

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER

1. NAME OF THE MEDICINAL PRODUCT

Oxybutynin Hydrochloride 2.5 mg Tablets

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Maxwellia

3. EXPIRY DATE

EXP: mm/yyyy

4. BATCH NUMBER

Batch : XXXX

5. OTHER

TABLE OF CONTENT OF THE PAR UPDATE

Steps taken after the initial procedure with an influence on the Public Assessment Report (non-safety variations of clinical significance).

Please note that only non-safety variations of clinical significance are recorded below and in the annexes to this PAR. The assessment of safety variations where significant changes are made are recorded on the MHRA website or European Medicines Agency (EMA) website. Minor changes to the marketing authorisation are recorded in the current SmPC and/or PIL available on the MHRA website.

Application type	**Scope**	**Product information affected**	**Date of grant**	**Outcome**	**Assessment report attached Y/N**
Reclassification	To change the legal status from POM to P, and consequential / associated changes which were also not carried forward due to the over-arching reclassification refusal. .	N/A	N/A	**refused**	N